Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Tie-up with Kowa Could Evolve into Full Integration: Mr Tamura of Nikken Chemicals
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 3, 2004
- 6 New Drugs Including Visdyne Added to the NHI Price List
May 3, 2004
- PRESS SEMINAR
May 3, 2004
- REGULATORY NEWS IN BRIEF
May 3, 2004
- BULLETIN
May 3, 2004
- JRCS to Build Large-scale Clinical Trial Network
May 3, 2004
- OTC NEWS IN BRIEF
May 3, 2004
- Terumo Aims for 10th Consecutive Year of Growth in FY2004
May 3, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 3, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 3, 2004
- WORLD NEWS IN BRIEF
May 3, 2004
- Meet the Leaders (32)
May 3, 2004
- AstraZeneca Committed to Maintaining Top Position in Oncology
May 3, 2004
- Tokushukai Group to Establish Large-scale Clinical Trial Network
May 3, 2004
- Sankyo Aims for \15 Bil. Sales in China by 2010
May 3, 2004
- JOS Prepares Photodynamic Therapy GL
May 3, 2004
- FPMAJ Petitions for 8-Year Data Protection Period for New Drugs
May 3, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 3, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…